ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1074

High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis

Giuliana Ascone1, Irene Di Ceglie1, Arjen B. Blom1, Birgitte Walgreen2, Annet W. Sloetjes1, Peter M. van der Kraan1, Ernst Lindhout3, Mike Martens3 and Peter L. van Lent4, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Experimental, Radboud university medical center, Nijmegen, Netherlands, 3Future Diagnostics Solutions (FDs), Wijchen, Netherlands, 4Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, Bone, Cholesterol, osteoclasts and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by immune complex- deposition in the synovium, leading to increased bone destruction. In RA, joint destruction has been associated with high cholesterol levels, largely transported in low density lipoprotein (LDL) particles and enhanced LDL oxidation (oxLDL). Apolipoprotein E (Apo E) is an important regulator of LDL transportation and its absence strongly elevates LDL levels in the serum, which may lead to increased oxLDL levels during inflammation. In this study, we investigated the effects of high LDL levels on bone destruction during antigen-induced arthritis (AIA), which is largely immune complex driven and how increased LDL/oxLDL levels affect osteoclast formation.


Methods: AIA was induced by injection of methylated BSA (mBSA) into the right knee joint of Apo E-/- and wild type (WT) control mice previously immunized with mBSA and complete Freund’s adjuvant (CFA). WT and ApoE -/- Hoxb8 myeloid precursor cells were differentiated into osteoclasts using 20 ng/mL RANKL and 30 ng/mL M-CSF, then stimulated for 24h with 10 µg/mL LDL/oxLDL. Oil Red O staining was performed to assess lipid uptake by osteoclasts. mRNA levels of NFATc1, DC-STAMP, TRAP, CTR and Cat K were measured by qPCR, whereas TRAP activity in culture supernatants was detected using a spectrophotometric assay. Bone erosion was quantified by histological analysis using an arbitrary scale from 0 to 3 and TRAP+ cells were determined using immunohistochemistry.


Results: Apo E-/- mice showed significantly higher LDL serum levels than WT controls. Histology showed that at day 21 after AIA induction, bone destruction was significantly decreased in the Apo E-/- mice, as indicated by the reduction of erosion pits (25% reduction from 1.5±0.2 to 1.1 ±0.1). ). In line with that, ApoE-/- mice showed a lower number of osteoclasts within the knee joints (36% lower from 20±4 osteoclasts/section in WT mice to 12±5 in ApoE-/- mice), as determined by image analysis of TRAP staining. To study the role of ApoE and high LDL levels on osteoclastogenesis in more detail, we differentiated WT and ApoE-/- myeloid precursor cells (Hoxb8) into osteoclasts and found similar mRNA levels of osteoclast markers. Whereas the number of osteoclasts was comparable between WT and ApoE-/- osteoclasts, we observed significantly decreased mRNA expression of TRAP (2.6 fold decrease) in ApoE-/- cells as compared to WT cells. In line with this, TRAP activity was reduced by 49%, suggesting a decreased osteoclast activity in ApoE-/- cells. Stimulation of osteoclasts by oxLDL strongly impaired cell fusion keeping them in a mononuclear state. mRNA levels of DC-STAMP were significantly down-regulated in both WT and ApoE-/- osteoclasts (1.4 and 2.3 fold decrease, respectively) as well as TRAP activity (49% and 58% reduction in WT and ApoE-/- osteoclasts, respectively), indicating a major role of oxLDL in the inhibition of osteoclastogenesis.


Conclusion: High LDL/oxLDL levels by apoE deficiency affect bone destruction by reducing the number of osteoclasts within the synovium during AIA probably by interfering osteoclastogenesis.


Disclosure: G. Ascone, None; I. Di Ceglie, None; A. B. Blom, None; B. Walgreen, None; A. W. Sloetjes, None; P. M. van der Kraan, None; E. Lindhout, None; M. Martens, None; P. L. van Lent, None.

To cite this abstract in AMA style:

Ascone G, Di Ceglie I, Blom AB, Walgreen B, Sloetjes AW, van der Kraan PM, Lindhout E, Martens M, van Lent PL. High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/high-cholesterol-levels-by-apoe-defenciency-reduce-bone-destruction-in-murine-antigen-induced-arthritis-via-inhibition-of-osteoclastogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-cholesterol-levels-by-apoe-defenciency-reduce-bone-destruction-in-murine-antigen-induced-arthritis-via-inhibition-of-osteoclastogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology